Ruipu Biotech released its 2026 interim report. Total operating revenue was 1.72 billion yuan, and net profit attributable to the parent company was 204 million yuan, a decrease of 52.417 million yuan from the same period last year, down 20.43% year on year. Net cash inflow from operating activities was 194 million yuan. The asset-liability ratio was 34.40%. Gross margin was 39.73%, down 2.33 percentage points from the same period last year. ROE was 4.34%, down 1.29 percentage points from the same period last year. Diluted earnings per share were 0.45 yuan, down 20.33% year on year. The company had 22,300 shareholders, and the top ten shareholders held 53.59% of total share capital.
Tianjin Ringpu Bio TechNet profit fell 20.43% year on year, with lower gross margin and ROE.